| Similar Articles |
|---|
 |
The Motley Fool
January 31, 2007
Brian Lawler |
No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note.   |
The Motley Fool
October 31, 2007
Brian Orelli |
A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note. |
The Motley Fool
October 26, 2004
Charly Travers |
Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land? |
The Motley Fool
July 21, 2006
Brian Lawler |
Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
BusinessWeek
June 11, 2007
Mara Der Hovanesian |
Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta. |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
The Motley Fool
December 17, 2004
Brian Gorman |
Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls. |
The Motley Fool
August 25, 2010
Brian Orelli |
Shares Soar! That'll Help Investors Sleep Better Tonight. Somaxon finds a marketing partner for its insomnia drug. |
The Motley Fool
July 30, 2007
Brian Orelli |
Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future. |
The Motley Fool
November 17, 2006
Billy Fisher |
Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock. |
The Motley Fool
February 17, 2005
Karl Thiel |
Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
BusinessWeek
May 31, 2004
Gene G. Marcial |
Seeking Sepracor? Sepracor is takeover bait because it is just what Big Pharma wants: diversified drugs and the newly approved sleep-disorder medication with blockbuster potential, Estorra. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
September 26, 2007
Billy Fisher |
More Than 40 Winks From Arena The company announced positive preliminary results from its phase 2 clinical trial for APD125, which aims to treat people suffering from chronic insomnia. Investors, take note. |
The Motley Fool
August 13, 2004
Charly Travers |
Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
The Motley Fool
July 24, 2006
Stephen D. Simpson |
Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note. |
BusinessWeek
April 23, 2007
Alex Halperin |
Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review. |
BusinessWeek
July 2, 2007
Arlene Weintraub |
Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound. |
The Motley Fool
August 30, 2004
Charly Travers |
It's a Hard-Knock Market You can never eliminate the risk in investing, but you can manage risk by understanding where you're putting your money. |
The Motley Fool
March 9, 2004
David Nierengarten |
Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%. |
ifeminists
September 14, 2005
Tony Zizza |
Lunesta Lunacy Big Pharma will not stop telling us that we need countless prescription medicines to treat all that troubles us unless we actually take the time to listen to what we're being told. To believe that as adults we need Lunesta to cope with electric bills is lunacy. |
BusinessWeek
January 26, 2004
Arlene Weintraub |
"I Can't Sleep" Insomnia and other sleep disorders are wreaking havoc on our health and taxing the economy. Drug companies see an opportunity. |
The Motley Fool
July 16, 2007
Brian Orelli |
Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price. |
